Andrew Behm

Title: Innovative Contributions of Andrew Behm in Specialty Drug Identification

Introduction: Andrew Behm is an accomplished inventor based in Minneapolis, MN, with a notable contribution to the field of pharmaceutical science. With two patents to his name, his work primarily focuses on the identification of specialty drugs, which are critical for effective patient treatment and healthcare management.

Latest Patents: Andrew's latest patents revolve around methods for determining whether a drug qualifies as a specialty drug. These patents disclose various methodologies for creating tools necessary for this determination, as well as the tools themselves. The overall value of a drug is assessed based on a set of attributes, which include its route of administration, the targeted disease, potential adverse reactions, toxicity risks, cost implications, and requirements for patient compliance with treatment. If a drug meets specific criteria regarding its overall or partial value based on these attributes, it is classified as a specialty drug.

Career Highlights: Andrew Behm is currently employed at Express Scripts, Inc., where he leverages his expertise in pharmaceuticals to aid in drug evaluation processes. His work significantly enhances the understanding and identification of specialty drugs, directly impacting patient care and treatment options.

Collaborations: Throughout his career, Andrew has collaborated with esteemed colleagues, including Edmond Weisbart and Aimee Tharaldson. Together, they strive to innovate and improve methods in drug identification, contributing to advancements in pharmacology and patient services.

Conclusion: Andrew Behm's contributions to the field of specialty drug identification exemplify the innovative spirit that drives progress in healthcare. With his valuable patents and collaborative efforts, he continues to play a pivotal role in ensuring that patients receive the most effective treatments available.